The FDA has granted full approval to generic dapagliflozin manufactured by Apotex Corp., paving the way for the company to capture market share in the widely prescribed SGLT2 inhibitor class. This entry is expected to intensify competitive pricing pressure on existing branded formulations following a significant patent cliff in 2024.